Korro Bio announced substantial workforce reductions and a strategic pivot after its RNA‑editing lead program failed to meet potency expectations in early testing. The company said it will cut roughly one‑third of staff and pause parts of its research collaboration with Novo Nordisk to preserve cash and extend runway. Korro also disclosed it is discontinuing the development of the underperforming candidate and will re‑prioritize resources toward other pipeline candidates, including a newly nominated development candidate for hyperammonemia. The combined operational moves triggered a dramatic share decline and reflect how early clinical disappointments can force mid‑stage biotechs into rapid restructuring to survive.